Israel - hebraisk - Ministry of Health

unipharm ltd, israel - pravastatin sodium - טבליה - pravastatin sodium 40 mg - pravastatin - pravastatin - pravastatin is indicated as a component of multiple risk factor intervention in those individuals at increased risk for atherosclerotic vascular disease due to hypercholesterolemia . pravastatin should be used in addition to a diet other nonpharmacological measures alone have been inadequate. primary prevention of coronary events: in hypercholesterolemic patients wihthout clinically evident coronary heart disease pravastatin is indicated to: 1) reduce the risk of myocardial infarcton. 2) reduce the risk for revascularization. 3) reduce the risk of deaths due to cardiovascular causes with no increase in death due to non-cardiovascular causes. secondary prevention of cardiovascular events: a) atherosclerosis: in hypercholesterolemic patients with clinically evident coronary artery disease including prior mi pravastatin is indicated to: 1)slow the progression of coronary atherosclerosis. 2) reduce the risk of acute coronary events. b) myocardial infarction: in patients with previous myocardial infarction and nor

Israel - hebraisk - Ministry of Health

unipharm ltd, israel - pravastatin sodium - טבליה - pravastatin sodium 10 mg - pravastatin - pravastatin - pravastatin is indicated as a component of multiple risk factor intervention in those individuals at increased risk for atherosclerotic vascular disease due to hypercholesterolemia . pravastatin should be used in addition to a diet and other nonpharmacological measures alone has been inadequate. primary prevention of coronary events: in hypercholesterolemic patients wihthout clinically evident coronary heart disease pravastatin is indicated to: 1) reduce the risk of myocardial infarcton. 2) reduce the risk for revascularization. 3) reduce the risk of deaths due to cardiovascular causes with no increase in death non-cardiovascular causes. secondary prevention of cardiovascular events: a) atherosclerosis: in hypercholesterolemic patients with clinically evident coronary artery disease including prior mi pravastatin is indicated to: 1)slow the progression of coronary atherosclerosis. 2) reduce the risk of acute coronary events. b) myocardial infarction: in patients with previous myocardial infarction and normal

Israel - hebraisk - Ministry of Health

unipharm ltd, israel - pravastatin sodium - טבליה - pravastatin sodium 20 mg - pravastatin

Israel - hebraisk - Ministry of Health

mbi pharma ltd., israel - chenodeoxycholic acid - קפסולה קשיחה - chenodeoxycholic acid 250 mg - chenodeoxycholic acid

Israel - hebraisk - Ministry of Health

ferring pharmaceuticals ltd - triptorelin as embonate - suspension for injection - triptorelin as embonate 3.75 mg ml - triptorelin - triptorelin - lowering of sexual hormones and treatment of advanced prostate cancer. central precocious puberty.

Israel - hebraisk - Ministry of Health

ferring pharmaceuticals ltd - triptorelin as embonate - suspension for injection - triptorelin as embonate 11.25 mg - triptorelin - triptorelin - prostatic cancer and lowering of sexual hormones.

Israel - hebraisk - Ministry of Health

ferring pharmaceuticals ltd - triptorelin as embonate - אבקה וממס להכנת תרחיף להזרקה - triptorelin as embonate 22.5 mg - triptorelin

Israel - hebraisk - Ministry of Health

unipharm ltd, israel - cilazapril - טבליה - cilazapril 2.5 mg - cilazapril - cilazapril - a blood pressure lowering agent. chronic heart failure.

Israel - hebraisk - Ministry of Health

unipharm ltd, israel - cilazapril - טבליה - cilazapril 5 mg - cilazapril - cilazapril - a blood pressure lowering agent. chronic heart failure.

Israel - hebraisk - Ministry of Health

unipharm ltd, israel - cilazapril; hydrochlorothiazide - טבליה - cilazapril 5 mg; hydrochlorothiazide 12.5 mg - cilazapril - cilazapril - treatment of essential hypertension in patients who have been stabilized on the individual components given in the same proportions.